Neoflavonoids and Tetrahydroquinolones as Possible Cancer Chemopreventive Agents

Chemical Biology and Drug Design

Volumn 80, Issue 4, 2012, Pages 616-624

  Luqman, Suaib ^a   Meena, Abha ^a   Singh, Pragya ^a   Kondratyuk, Tamara P ^b   Marler, Laura E ^b   Pezzuto, John M ^b   Negi, Arvind S ^a  

^a CSIR CENTRAL INSTITUTE OF MEDICINAL AND AROMATIC PLANTS   (India)

^b UNIVERSITY OF HAWAII AT HILO   (United States)

Author keywords

Aromatase; Cancer chemoprevention; Neoflavonoids; NF B; Quinone reductase 1; Tetrahydroquinoline

Indexed keywords

AROMATASE; FLAVONOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTAM DERIVATIVE; LACTONE DERIVATIVE; QUINOLONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOASSAY; CANCER PREVENTION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG SYNTHESIS; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; ANTICARCINOGENIC AGENTS; AROMATASE INHIBITORS; CELL LINE, TUMOR; FLAVONOIDS; HEK293 CELLS; HUMANS; MICE; MOLECULAR DOCKING SIMULATION; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASMS; NF-KAPPA B; QUINOLONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866613430     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2012.01439.x     Document Type: Article

References (22)

1. Irigaray P., Belpomme D. (2010) Basic properties and molecular mechanisms of exogenous chemical carcinogens. Carcinogenesis;31:135-148.
2. Gullett N.P., Ruhul Amin A.R., Bayraktar S., Pezzuto J.M., Shin D.M., Khuri F.R., Aggarwal B.B., Surh Y.J., Kucuk O. (2010) Cancer prevention with natural compounds. Semin Oncol;37:258-281.
3. Luqman S., Pezzuto J.M. (2010) NFkappaB: a promising target for natural products in cancer chemoprevention. Phytother Res;24:949-963.
4. Inoue J., Gohda J., Akiyama T., Semba K. (2007) NF-κB activation in development and progression of cancer. Cancer Sci;98:268-274.
5. Yamamoto Y., Gaynor R.B. (2001) Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest;107:135-142.
6. Mamett L. (1992) Aspirin and the potential role of prostaglandins in colon cancer. J Cancer Res;52:5575-5589.
7. Maiti A., Reddy P.V., Sturdy M., Marler L., Pegan S.D., Mesecar A.D., Pezzuto J.M., Cushman M. (2009) Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem;52:1873-1884.
8. Strasser-Weippl K., Goss P.E. (2005) Counteracting estrogen as breast cancer prevention. In: Kelloff G.J., Hawk E.T., Sigman C.C., editors. Cancer Chemoprevention, Vol. 2. Totowa, NJ: Humana Press, Inc.; p. 249-264.
9. Recanatini M., Cavalli A., Valenti P. (2002) Nonsteroidal aromatase inhibitors: recent advances. Med Res Rev;22:282-304.
10. Fahey J.W., Zhang Y., Talalay P. (1997) Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci U S A;94:10367-10372.
11. Pezzuto J.M. (1995) Recent advances in phytochemistry. In: Arnason J., Mata R., Romeo J., editors. Phytochemistry of Medicinal Plants, Vol. 29. New York: Plenum Press; p. 19-44.
12. Singh P., Faridi U., Srivastava S., Kumar J.K., Darokar M.P., Luqman S., Shanker K., Chanotiya C.S., Gupta A., Gupta M.M., Negi A.S. (2010) Design and synthesis of C-ring lactone- and lactam-based podophyllotoxin analogues as anticancer agents. Chem Pharm Bull;58:242-246.
13. Morais M.C.C., Luqman S., Kondratyuk T.P., Petronio M.S., Regasini L.O., Silva D.H.S., Bolzani V.S., Soares C.P., Pezzuto J.M. (2010) Suppression of TNF-α induced NFκB activity by gallic acid and its semi-synthetic alkyl-gallates: possible role in cancer chemoprevention. Nat Prod Res;24:1758-1765.
14. Song L.L., Kosmeder J.W. II, Lee S.K., Gerhauser C., Lantvit D., Moon R.C., Moriarty R.M., Pezzuto J.M. (1999) Cancer chemopreventive activity mediated by 4′-bromoflavone, a potent inducer of phase II detoxification enzymes. Cancer Res;59:578-585.
15. Lipinski C.A. (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods;44:235-49.
16. Lipinski C.A., Lombardo F., Dominy B.W., Fenney P.J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev;46:3-26.
17. Block G., Patterson B., Subar A. (1992) Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer;18:1-29.
18. Sullivan J.C., Wolenski F.S., Reitzel A.M., French C.E., Traylor-Knowles N., Gilmore T.D., Finnerty J.R. (2009) Two alleles of NF-kappaB in the sea anemone Nematostella vectensis are widely dispersed in nature and encode proteins with distinct activities. PLoS ONE;4:e7311.
19. Kinghorn A.D., Su B.N., Jang D.S., Chang L.C., Lee D., Gu J.Q., Carcache-Blanco E.J. et al. (2004) Natural inhibitors of carcinogenesis. Planta Med;70:691-705.
20. Pommier Y., Leo E., Zhang H., Marchand C. (2010) DNA topoisomerases and their anticancer and antibacterial inhibitors. Chem Biol;17:421-433.
21. Norinder U., Österberg T., Artursson P. (1999) Theoretical calculation and prediction of intestinal absorption of drugs in humans using MolSurf parametrization and PLS statistics. Eur J Pharm Sci;8:49-56.
22. Ertl P., Rohde B., Selzer P. (2000) Fast calculation of molecular polar surface area as a sum of fragment based contribution and its application to the prediction of drug transport properties. J Med Chem;43:3714-3717.